Biogen to launch Phase IV study of spinal muscular atrophy drug in post-gene therapy patients

Biogen to launch Phase IV study of spinal muscular atrophy drug in post-gene therapy patients

Source: 
MedCity News
snippet: 

The company plans to enroll 60 patients who have received its drug, Spinraza, following suboptimal response to Novartis' Zolgensma, which was approved last year. The trial, RESPOND, is anticipated to start enrolling in the first quarter of 2021, pending regulatory approval.